NR3C1 and cancer: In patients with bladder cancer, we found that a loss of strong GR expression (i.e., 0/1+ or 0/1+/2+) was also associated with considerably higher risks for the recurrence of non-muscle-invasive tumors and progression of cancer-specific mortality of the muscle-invasive tumors [24].